ID   KS6A1_HUMAN             Reviewed;         735 AA.
AC   Q15418; A6NGG4; A8K9K7; B2RDY8; B7Z5J0; E9PRI4; Q5SVM5; Q5SVM8;
AC   Q5SVM9; Q96C05; Q9BQK2;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   12-APR-2017, entry version 186.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-1;
DE            Short=S6K-alpha-1;
DE            EC=2.7.11.1;
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 1;
DE            Short=p90-RSK 1;
DE            Short=p90RSK1;
DE            Short=p90S6K;
DE   AltName: Full=MAP kinase-activated protein kinase 1a;
DE            Short=MAPK-activated protein kinase 1a;
DE            Short=MAPKAP kinase 1a;
DE            Short=MAPKAPK-1a;
DE   AltName: Full=Ribosomal S6 kinase 1;
DE            Short=RSK-1;
GN   Name=RPS6KA1; Synonyms=MAPKAPK1A, RSK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-335.
RX   PubMed=8141249;
RA   Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.;
RT   "Human rsk isoforms: cloning and characterization of tissue-specific
RT   expression.";
RL   Am. J. Physiol. 266:C351-C359(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Testis, and Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9687510; DOI=10.1093/emboj/17.15.4426;
RA   Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.;
RT   "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly
RT   activated by MAPK and SAPK2/p38, and may mediate activation of CREB.";
RL   EMBO J. 17:4426-4441(1998).
RN   [7]
RP   FUNCTION, ENZYME REGULATION, AND PHOSPHORYLATION AT SER-221; THR-359;
RP   SER-363; SER-380; THR-573 AND SER-732.
RX   PubMed=9430688; DOI=10.1074/jbc.273.3.1496;
RA   Dalby K.N., Morrice N., Caudwell F.B., Avruch J., Cohen P.;
RT   "Identification of regulatory phosphorylation sites in mitogen-
RT   activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk
RT   that are inducible by MAPK.";
RL   J. Biol. Chem. 273:1496-1505(1998).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF BAD.
RX   PubMed=10679322; DOI=10.1016/S0960-9822(00)00310-9;
RA   Shimamura A., Ballif B.A., Richards S.A., Blenis J.;
RT   "Rsk1 mediates a MEK-MAP kinase cell survival signal.";
RL   Curr. Biol. 10:127-135(2000).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CEBPB.
RX   PubMed=11684016; DOI=10.1016/S1097-2765(01)00374-4;
RA   Buck M., Poli V., Hunter T., Chojkier M.;
RT   "C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase
RT   inhibitory box critical for cell survival.";
RL   Mol. Cell 8:807-816(2001).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF ETV1/ER81, AND INTERACTION WITH
RP   ETV1/ER81.
RX   PubMed=12213813; DOI=10.1074/jbc.M205501200;
RA   Wu J., Janknecht R.;
RT   "Regulation of the ETS transcription factor ER81 by the 90-kDa
RT   ribosomal S6 kinase 1 and protein kinase A.";
RL   J. Biol. Chem. 277:42669-42679(2002).
RN   [11]
RP   INTERACTION WITH MAPK1 OR MAPK3.
RX   PubMed=12832467; DOI=10.1128/MCB.23.14.4796-4804.2003;
RA   Roux P.P., Richards S.A., Blenis J.;
RT   "Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates
RT   extracellular signal-regulated kinase docking and RSK activity.";
RL   Mol. Cell. Biol. 23:4796-4804(2003).
RN   [12]
RP   FUNCTION, INTERACTION WITH FGFR1, ENZYME REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15117958; DOI=10.1074/jbc.M311144200;
RA   Hu Y., Fang X., Dunham S.M., Prada C., Stachowiak E.K.,
RA   Stachowiak M.K.;
RT   "90-kDa ribosomal S6 kinase is a direct target for the nuclear
RT   fibroblast growth factor receptor 1 (FGFR1): role in FGFR1
RT   signaling.";
RL   J. Biol. Chem. 279:29325-29335(2004).
RN   [13]
RP   FUNCTION IN MTOR SIGNALING, AND INTERACTION WITH TSC2.
RX   PubMed=15342917; DOI=10.1073/pnas.0405659101;
RA   Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J.;
RT   "Tumor-promoting phorbol esters and activated Ras inactivate the
RT   tuberous sclerosis tumor suppressor complex via p90 ribosomal S6
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:13489-13494(2004).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF DAPK1.
RX   PubMed=16213824; DOI=10.1016/j.cub.2005.08.050;
RA   Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.;
RT   "The tumor suppressor DAP kinase is a target of RSK-mediated survival
RT   signaling.";
RL   Curr. Biol. 15:1762-1767(2005).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF NR4A1/NUR77.
RX   PubMed=16223362; DOI=10.1042/BJ20050967;
RA   Wingate A.D., Campbell D.G., Peggie M., Arthur J.S.;
RT   "Nur77 is phosphorylated in cells by RSK in response to mitogenic
RT   stimulation.";
RL   Biochem. J. 393:715-724(2006).
RN   [16]
RP   FUNCTION IN TRANSLATION REGULATION, AND FUNCTION IN PHOSPHORYLATION OF
RP   EIF4B.
RX   PubMed=16763566; DOI=10.1038/sj.emboj.7601166;
RA   Shahbazian D., Roux P.P., Mieulet V., Cohen M.S., Raught B.,
RA   Taunton J., Hershey J.W., Blenis J., Pende M., Sonenberg N.;
RT   "The mTOR/PI3K and MAPK pathways converge on eIF4B to control its
RT   phosphorylation and activity.";
RL   EMBO J. 25:2781-2791(2006).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6.
RX   PubMed=17360704; DOI=10.1074/jbc.M700906200;
RA   Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J.,
RA   Sonenberg N., Blenis J.;
RT   "RAS/ERK signaling promotes site-specific ribosomal protein S6
RT   phosphorylation via RSK and stimulates cap-dependent translation.";
RL   J. Biol. Chem. 282:14056-14064(2007).
RN   [19]
RP   FUNCTION IN MTOR SIGNALING.
RX   PubMed=18722121; DOI=10.1016/j.cub.2008.07.078;
RA   Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E.,
RA   Thibault P., Roux P.P.;
RT   "Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-
RT   mediated raptor phosphorylation.";
RL   Curr. Biol. 18:1269-1277(2008).
RN   [20]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=18508509; DOI=10.2741/3003;
RA   Carriere A., Ray H., Blenis J., Roux P.P.;
RT   "The RSK factors of activating the Ras/MAPK signaling cascade.";
RL   Front. Biosci. 13:4258-4275(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-363 AND
RP   SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=18813292; DOI=10.1038/nrm2509;
RA   Anjum R., Blenis J.;
RT   "The RSK family of kinases: emerging roles in cellular signalling.";
RL   Nat. Rev. Mol. Cell Biol. 9:747-758(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-363; SER-369
RP   AND SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-307; THR-359;
RP   SER-363; SER-369 AND SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359 AND SER-363, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-363; SER-369
RP   AND SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363 AND SER-380, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF EPHA2.
RX   PubMed=26158630; DOI=10.1038/ncomms8679;
RA   Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y.,
RA   Yano S., Fukuoka J., Koizumi K., Saiki I., Sakurai H.;
RT   "Crucial roles of RSK in cell motility by catalysing serine
RT   phosphorylation of EphA2.";
RL   Nat. Commun. 6:7679-7679(2015).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 33-353 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=17965187; DOI=10.1110/ps.073123707;
RA   Ikuta M., Kornienko M., Byrne N., Reid J.C., Mizuarai S., Kotani H.,
RA   Munshi S.K.;
RT   "Crystal structures of the N-terminal kinase domain of human RSK1
RT   bound to three different ligands: Implications for the design of RSK1
RT   specific inhibitors.";
RL   Protein Sci. 16:2626-2635(2007).
RN   [32]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-335.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of
CC       ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic
CC       and stress-induced activation of the transcription factors CREB1,
CC       ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and
CC       EIF4B phosphorylation, and mediates cellular proliferation,
CC       survival, and differentiation by modulating mTOR signaling and
CC       repressing pro-apoptotic function of BAD and DAPK1. In fibroblast,
CC       is required for EGF-stimulated phosphorylation of CREB1, which
CC       results in the subsequent transcriptional activation of several
CC       immediate-early genes. In response to mitogenic stimulation (EGF
CC       and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81
CC       transcription factors and the cofactor CREBBP. Upon insulin-
CC       derived signal, acts indirectly on the transcription regulation of
CC       several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting
CC       its activity. Phosphorylates RPS6 in response to serum or EGF via
CC       an mTOR-independent mechanism and promotes translation initiation
CC       by facilitating assembly of the pre-initiation complex. In
CC       response to insulin, phosphorylates EIF4B, enhancing EIF4B
CC       affinity for the EIF3 complex and stimulating cap-dependent
CC       translation. Is involved in the mTOR nutrient-sensing pathway by
CC       directly phosphorylating TSC2 at 'Ser-1798', which potently
CC       inhibits TSC2 ability to suppress mTOR signaling, and mediates
CC       phosphorylation of RPTOR, which regulates mTORC1 activity and may
CC       promote rapamycin-sensitive signaling independently of the
CC       PI3K/AKT pathway. Mediates cell survival by phosphorylating the
CC       pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-
CC       apoptotic function. Promotes the survival of hepatic stellate
CC       cells by phosphorylating CEBPB in response to the hepatotoxin
CC       carbon tetrachloride (CCl4). Mediates induction of hepatocyte
CC       prolifration by TGFA through phosphorylation of CEBPB (By
CC       similarity). Is involved in cell cycle regulation by
CC       phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B
CC       association with 14-3-3 proteins and prevents its translocation to
CC       the nucleus and inhibition of G1 progression. Phosphorylates EPHA2
CC       at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell
CC       migration (PubMed:26158630). {ECO:0000250|UniProtKB:P18653,
CC       ECO:0000250|UniProtKB:Q63531, ECO:0000269|PubMed:10679322,
CC       ECO:0000269|PubMed:11684016, ECO:0000269|PubMed:12213813,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:15342917,
CC       ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362,
CC       ECO:0000269|PubMed:16763566, ECO:0000269|PubMed:17360704,
CC       ECO:0000269|PubMed:18722121, ECO:0000269|PubMed:26158630,
CC       ECO:0000269|PubMed:9430688}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Upon extracellular signal or mitogen
CC       stimulation, phosphorylated at Thr-573 in the C-terminal kinase
CC       domain (CTKD) by MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD
CC       then autophosphorylates Ser-380, allowing binding of PDPK1, which
CC       in turn phosphorylates Ser-221 in the N-terminal kinase domain
CC       (NTDK) leading to the full activation of the protein and
CC       subsequent phosphorylation of the substrates by the NTKD.
CC       {ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:9430688}.
CC   -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in
CC       quiescent cells. Transiently dissociates following mitogenic
CC       stimulation. Interacts with ETV1/ER81 and FGFR1.
CC       {ECO:0000269|PubMed:12213813, ECO:0000269|PubMed:12832467,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:15342917,
CC       ECO:0000269|PubMed:17965187}.
CC   -!- INTERACTION:
CC       O43823:AKAP8; NbExp=5; IntAct=EBI-963034, EBI-1237481;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-963034, EBI-352572;
CC       P50552:VASP; NbExp=4; IntAct=EBI-963034, EBI-748201;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q15418-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15418-2; Sequence=VSP_041380;
CC       Name=3;
CC         IsoId=Q15418-3; Sequence=VSP_041580;
CC         Note=No experimental confirmation available.;
CC       Name=4 {ECO:0000305};
CC         IsoId=Q15418-4; Sequence=VSP_057469;
CC   -!- PTM: Activated by phosphorylation at Ser-221 by PDPK1.
CC       Autophosphorylated on Ser-380, as part of the activation process.
CC       May be phosphorylated at Thr-359 and Ser-363 by MAPK1/ERK2 and
CC       MAPK3/ERK1. {ECO:0000269|PubMed:9430688}.
CC   -!- PTM: N-terminal myristoylation results in an activated kinase in
CC       the absence of added growth factors.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RPS6KA1ID43477ch1p36.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07597; AAC82497.1; -; mRNA.
DR   EMBL; AK292722; BAF85411.1; -; mRNA.
DR   EMBL; AK299007; BAH12926.1; -; mRNA.
DR   EMBL; AK315730; BAG38085.1; -; mRNA.
DR   EMBL; AL109743; CAC36348.1; -; Genomic_DNA.
DR   EMBL; AL627313; CAI14647.1; -; Genomic_DNA.
DR   EMBL; AL627313; CAI14648.1; -; Genomic_DNA.
DR   EMBL; AL627313; CAI14649.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07799.1; -; Genomic_DNA.
DR   EMBL; BC014966; AAH14966.1; -; mRNA.
DR   CCDS; CCDS284.1; -. [Q15418-1]
DR   CCDS; CCDS30649.1; -. [Q15418-2]
DR   CCDS; CCDS81286.1; -. [Q15418-4]
DR   PIR; I51901; I51901.
DR   RefSeq; NP_001006666.1; NM_001006665.1. [Q15418-2]
DR   RefSeq; NP_001317370.1; NM_001330441.1. [Q15418-4]
DR   RefSeq; NP_002944.2; NM_002953.3. [Q15418-1]
DR   UniGene; Hs.149957; -.
DR   PDB; 2WNT; X-ray; 2.40 A; A/B=413-719.
DR   PDB; 2Z7Q; X-ray; 2.00 A; A=33-353.
DR   PDB; 2Z7R; X-ray; 2.00 A; A=33-353.
DR   PDB; 2Z7S; X-ray; 2.10 A; A=33-353.
DR   PDB; 3RNY; X-ray; 2.70 A; A/B=411-735.
DR   PDB; 3TEI; X-ray; 2.40 A; B=712-735.
DR   PDB; 4H3P; X-ray; 2.30 A; B/E=712-735.
DR   PDB; 4NIF; X-ray; 2.15 A; A/D=411-735.
DR   PDB; 5CSF; X-ray; 2.40 A; C=683-735.
DR   PDB; 5CSI; X-ray; 2.13 A; C=689-735.
DR   PDB; 5CSJ; X-ray; 2.70 A; C=696-735.
DR   PDB; 5CSN; X-ray; 2.95 A; C=683-720.
DR   PDBsum; 2WNT; -.
DR   PDBsum; 2Z7Q; -.
DR   PDBsum; 2Z7R; -.
DR   PDBsum; 2Z7S; -.
DR   PDBsum; 3RNY; -.
DR   PDBsum; 3TEI; -.
DR   PDBsum; 4H3P; -.
DR   PDBsum; 4NIF; -.
DR   PDBsum; 5CSF; -.
DR   PDBsum; 5CSI; -.
DR   PDBsum; 5CSJ; -.
DR   PDBsum; 5CSN; -.
DR   ProteinModelPortal; Q15418; -.
DR   SMR; Q15418; -.
DR   BioGrid; 112109; 69.
DR   DIP; DIP-29987N; -.
DR   IntAct; Q15418; 30.
DR   MINT; MINT-207205; -.
DR   STRING; 9606.ENSP00000435412; -.
DR   BindingDB; Q15418; -.
DR   ChEMBL; CHEMBL2553; -.
DR   DrugBank; DB04751; Purvalanol A.
DR   GuidetoPHARMACOLOGY; 1527; -.
DR   iPTMnet; Q15418; -.
DR   PhosphoSitePlus; Q15418; -.
DR   BioMuta; RPS6KA1; -.
DR   DMDM; 20178306; -.
DR   UCD-2DPAGE; Q15418; -.
DR   EPD; Q15418; -.
DR   MaxQB; Q15418; -.
DR   PaxDb; Q15418; -.
DR   PeptideAtlas; Q15418; -.
DR   PRIDE; Q15418; -.
DR   DNASU; 6195; -.
DR   Ensembl; ENST00000374168; ENSP00000363283; ENSG00000117676. [Q15418-1]
DR   Ensembl; ENST00000526792; ENSP00000431651; ENSG00000117676. [Q15418-3]
DR   Ensembl; ENST00000530003; ENSP00000432281; ENSG00000117676. [Q15418-4]
DR   Ensembl; ENST00000531382; ENSP00000435412; ENSG00000117676. [Q15418-2]
DR   Ensembl; ENST00000628081; ENSP00000487553; ENSG00000281877. [Q15418-4]
DR   Ensembl; ENST00000628256; ENSP00000487349; ENSG00000281877. [Q15418-2]
DR   Ensembl; ENST00000629832; ENSP00000486881; ENSG00000281877. [Q15418-1]
DR   Ensembl; ENST00000631108; ENSP00000487166; ENSG00000281877. [Q15418-3]
DR   GeneID; 6195; -.
DR   KEGG; hsa:6195; -.
DR   UCSC; uc001bmr.2; human. [Q15418-1]
DR   UCSC; uc057dso.1; human.
DR   CTD; 6195; -.
DR   DisGeNET; 6195; -.
DR   GeneCards; RPS6KA1; -.
DR   HGNC; HGNC:10430; RPS6KA1.
DR   HPA; CAB003852; -.
DR   HPA; HPA007981; -.
DR   MIM; 601684; gene.
DR   neXtProt; NX_Q15418; -.
DR   OpenTargets; ENSG00000117676; -.
DR   PharmGKB; PA34845; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00860000133668; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; Q15418; -.
DR   KO; K04373; -.
DR   OMA; PWITQKD; -.
DR   OrthoDB; EOG091G05Z7; -.
DR   PhylomeDB; Q15418; -.
DR   TreeFam; TF313438; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-199920; CREB phosphorylation.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-442742; CREB phosphorylation through the activation of Ras.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   SABIO-RK; Q15418; -.
DR   SignaLink; Q15418; -.
DR   SIGNOR; Q15418; -.
DR   ChiTaRS; RPS6KA1; human.
DR   EvolutionaryTrace; Q15418; -.
DR   GeneWiki; RPS6KA1; -.
DR   GenomeRNAi; 6195; -.
DR   PRO; PR:Q15418; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117676; -.
DR   CleanEx; HS_RPS6KA1; -.
DR   ExpressionAtlas; Q15418; baseline and differential.
DR   Genevisible; Q15418; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0072574; P:hepatocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:2000491; P:positive regulation of hepatic stellate cell activation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0043620; P:regulation of DNA-templated transcription in response to stress; TAS:UniProtKB.
DR   GO; GO:0043555; P:regulation of translation in response to stress; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Complete proteome; Cytoplasm; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Stress response; Transferase.
FT   CHAIN         1    735       Ribosomal protein S6 kinase alpha-1.
FT                                /FTId=PRO_0000086198.
FT   DOMAIN       62    321       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      322    391       AGC-kinase C-terminal.
FT   DOMAIN      418    675       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      68     76       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     424    432       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    187    187       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    535    535       Proton acceptor. {ECO:0000250}.
FT   BINDING      94     94       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     447    447       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      54     54       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     221    221       Phosphoserine; by PDPK1.
FT                                {ECO:0000305|PubMed:9430688}.
FT   MOD_RES     307    307       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     359    359       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:9430688}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:9430688}.
FT   MOD_RES     369    369       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     380    380       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:9430688}.
FT   MOD_RES     573    573       Phosphothreonine.
FT                                {ECO:0000269|PubMed:9430688}.
FT   MOD_RES     732    732       Phosphoserine.
FT                                {ECO:0000269|PubMed:9430688}.
FT   VAR_SEQ       1     92       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041580.
FT   VAR_SEQ       1     36       MPLAQLKEPWPLMELVPLDPENGQTSGEEAGLQPSK -> M
FT                                EQDPKPPRLRLWALIPWLPRKQRPRISQTSLPVPGPGSGPQ
FT                                RDS (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041380.
FT   VAR_SEQ       1     35       MPLAQLKEPWPLMELVPLDPENGQTSGEEAGLQPS -> MQ
FT                                TPADFPRVERDLVPCPR (in isoform 4).
FT                                /FTId=VSP_057469.
FT   VARIANT     335    335       K -> T (in dbSNP:rs2229712).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8141249}.
FT                                /FTId=VAR_021864.
FT   CONFLICT    609    609       A -> T (in Ref. 2; BAF85411).
FT                                {ECO:0000305}.
FT   CONFLICT    619    619       S -> G (in Ref. 2; BAF85411).
FT                                {ECO:0000305}.
FT   HELIX        59     61       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND       62     71       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND       74     81       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND       83     86       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND       90     96       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND      127    133       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND      136    141       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       149    156       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       161    180       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       190    192       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND      193    195       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND      197    199       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND      201    203       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       226    228       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       231    234       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       241    257       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       267    276       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       287    296       {ECO:0000244|PDB:2Z7Q}.
FT   TURN        301    303       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND      307    310       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       312    316       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       319    321       {ECO:0000244|PDB:2Z7Q}.
FT   HELIX       326    330       {ECO:0000244|PDB:2Z7Q}.
FT   STRAND      418    427       {ECO:0000244|PDB:4NIF}.
FT   STRAND      430    437       {ECO:0000244|PDB:4NIF}.
FT   TURN        438    441       {ECO:0000244|PDB:4NIF}.
FT   STRAND      442    450       {ECO:0000244|PDB:4NIF}.
FT   TURN        451    453       {ECO:0000244|PDB:4NIF}.
FT   HELIX       457    466       {ECO:0000244|PDB:4NIF}.
FT   STRAND      475    480       {ECO:0000244|PDB:4NIF}.
FT   STRAND      482    490       {ECO:0000244|PDB:4NIF}.
FT   HELIX       497    501       {ECO:0000244|PDB:4NIF}.
FT   STRAND      503    505       {ECO:0000244|PDB:3RNY}.
FT   HELIX       509    528       {ECO:0000244|PDB:4NIF}.
FT   HELIX       538    540       {ECO:0000244|PDB:4NIF}.
FT   STRAND      541    547       {ECO:0000244|PDB:4NIF}.
FT   HELIX       550    552       {ECO:0000244|PDB:4NIF}.
FT   STRAND      553    555       {ECO:0000244|PDB:4NIF}.
FT   TURN        574    576       {ECO:0000244|PDB:2WNT}.
FT   HELIX       583    609       {ECO:0000244|PDB:4NIF}.
FT   HELIX       622    631       {ECO:0000244|PDB:4NIF}.
FT   HELIX       639    642       {ECO:0000244|PDB:4NIF}.
FT   HELIX       646    655       {ECO:0000244|PDB:4NIF}.
FT   HELIX       660    662       {ECO:0000244|PDB:4NIF}.
FT   HELIX       666    671       {ECO:0000244|PDB:4NIF}.
FT   HELIX       673    676       {ECO:0000244|PDB:4NIF}.
FT   HELIX       678    680       {ECO:0000244|PDB:4NIF}.
FT   HELIX       691    706       {ECO:0000244|PDB:4NIF}.
FT   HELIX       717    719       {ECO:0000244|PDB:4NIF}.
FT   HELIX       721    726       {ECO:0000244|PDB:4NIF}.
SQ   SEQUENCE   735 AA;  82723 MW;  765731A4442A53DF CRC64;
     MPLAQLKEPW PLMELVPLDP ENGQTSGEEA GLQPSKDEGV LKEISITHHV KAGSEKADPS
     HFELLKVLGQ GSFGKVFLVR KVTRPDSGHL YAMKVLKKAT LKVRDRVRTK MERDILADVN
     HPFVVKLHYA FQTEGKLYLI LDFLRGGDLF TRLSKEVMFT EEDVKFYLAE LALGLDHLHS
     LGIIYRDLKP ENILLDEEGH IKLTDFGLSK EAIDHEKKAY SFCGTVEYMA PEVVNRQGHS
     HSADWWSYGV LMFEMLTGSL PFQGKDRKET MTLILKAKLG MPQFLSTEAQ SLLRALFKRN
     PANRLGSGPD GAEEIKRHVF YSTIDWNKLY RREIKPPFKP AVAQPDDTFY FDTEFTSRTP
     KDSPGIPPSA GAHQLFRGFS FVATGLMEDD GKPRAPQAPL HSVVQQLHGK NLVFSDGYVV
     KETIGVGSYS ECKRCVHKAT NMEYAVKVID KSKRDPSEEI EILLRYGQHP NIITLKDVYD
     DGKHVYLVTE LMRGGELLDK ILRQKFFSER EASFVLHTIG KTVEYLHSQG VVHRDLKPSN
     ILYVDESGNP ECLRICDFGF AKQLRAENGL LMTPCYTANF VAPEVLKRQG YDEGCDIWSL
     GILLYTMLAG YTPFANGPSD TPEEILTRIG SGKFTLSGGN WNTVSETAKD LVSKMLHVDP
     HQRLTAKQVL QHPWVTQKDK LPQSQLSHQD LQLVKGAMAA TYSALNSSKP TPQLKPIESS
     ILAQRRVRKL PSTTL
//
